All In Biotech

Free tool

FAERS Monitor: Lynavoy

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 220295 or its brand name (Lynavoy, Linerixibat). Reports on generic versions are filed under their own applications.

Reports

57

Serious

3

5% of reports

Hospitalization

2

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use25
  • diarrhoea14
  • drug interaction11
  • drug ineffective9
  • abdominal pain upper6
  • nausea4
  • product dose omission issue3
  • pruritus3
  • abdominal discomfort2
  • constipation2
  • intentional product misuse2
  • therapeutic product effect incomplete2
  • vomiting2
  • abdominal distension1
  • abdominal pain1

Reports by year received

View as table
YearReports
202657

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,102 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
drug interactionSignal1125.615.0238
abdominal pain upperSignal610.85.044
off label useSignal2510.57.9215
therapeutic product effect incomplete210.42.79
intentional product misuse28.42.27
diarrhoeaSignal148.05.181
abdominal discomfort24.41.12
product dose omission issue33.81.34
abdominal distension13.50.50
constipation23.40.91
pruritus32.91.02
drug ineffectiveSignal92.51.47
nausea41.90.71
abdominal pain11.60.20
vomiting21.60.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.